A

Ahn-Gook Pharmaceutical Co Ltd
KOSDAQ:001540

Watchlist Manager
Ahn-Gook Pharmaceutical Co Ltd
KOSDAQ:001540
Watchlist
Price: 7 990 KRW -0.37% Market Closed
Market Cap: 90.8B KRW

Relative Value

The Relative Value of one Ahn-Gook Pharmaceutical Co Ltd stock under the Base Case scenario is 21 312.02 KRW. Compared to the current market price of 7 990 KRW, Ahn-Gook Pharmaceutical Co Ltd is Undervalued by 63%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
21 312.02 KRW
Undervaluation 63%
Relative Value
Price
A
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
82
vs Industry
88
Median 3Y
0.4
Median 5Y
0.4
Industry
2.6
vs History
63
vs Industry
43
Median 3Y
11
Median 5Y
11.9
Industry
21.4
vs History
66
vs Industry
37
Median 3Y
2.4
Median 5Y
10.5
Industry
16.4
vs History
23
vs Industry
16
Median 3Y
-3.4
Median 5Y
-4.8
Industry
22.8
vs History
73
vs Industry
76
Median 3Y
0.6
Median 5Y
0.6
Industry
2.2
vs History
79
vs Industry
86
Median 3Y
0.4
Median 5Y
0.5
Industry
2.9
vs History
87
vs Industry
85
Median 3Y
0.6
Median 5Y
0.7
Industry
5.5
vs History
93
vs Industry
34
Median 3Y
7.2
Median 5Y
8.8
Industry
13
vs History
73
vs Industry
22
Median 3Y
13.4
Median 5Y
12.7
Industry
16.5
vs History
66
vs Industry
26
Median 3Y
3.2
Median 5Y
8.6
Industry
15.6
vs History
28
vs Industry
21
Median 3Y
-1.6
Median 5Y
-1.8
Industry
18.7
vs History
66
vs Industry
75
Median 3Y
0.5
Median 5Y
0.5
Industry
1.9

Multiples Across Competitors

Competitors Multiples
Ahn-Gook Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Ahn-Gook Pharmaceutical Co Ltd
KOSDAQ:001540
90.8B KRW 0.3 9.2 4.3 6.6
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.6 56.7 38 40.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.5B USD 5.4 19.8 16.2 21.1
CH
Roche Holding AG
SIX:ROG
268.8B CHF 4.4 28.5 12.1 14.2
UK
AstraZeneca PLC
LSE:AZN
219.6B GBP 5.1 31.5 108.7 159.1
US
Merck & Co Inc
NYSE:MRK
277.5B USD 4.3 14.6 10.3 12.2
CH
Novartis AG
SIX:NOVN
219.4B CHF 4.9 19.1 12.1 15.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.6 10.9 12.6
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.8B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
KR
A
Ahn-Gook Pharmaceutical Co Ltd
KOSDAQ:001540
Average P/E: 23.3
9.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
56.7
54%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.5
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.5
37%
0.9
US
Merck & Co Inc
NYSE:MRK
14.6
15%
1
CH
Novartis AG
SIX:NOVN
19.1
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.6
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
A
Ahn-Gook Pharmaceutical Co Ltd
KOSDAQ:001540
Average EV/EBITDA: 400.5
4.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.1
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.7
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
CH
Novartis AG
SIX:NOVN
12.1
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
A
Ahn-Gook Pharmaceutical Co Ltd
KOSDAQ:001540
Average EV/EBIT: 1 713.1
6.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.7
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.1
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5